Latest From Mallinckrodt PLC
AbbVie’s latest, largest acquisition may be cast in a new light as the pandemic throws stock markets into turmoil and commercial prospects up in the air.
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.
Despite the delay in a New York state opioid trial due to coronavirus, a motion has been filed to remove Mallinckrodt and SpecGx from proceedings. However, Nassau County opposed the motion.
The UK major is getting access to Silence's small interfering RNA (siRNA) platform while the London-based biotech is getting further validation of its technology and a considerable pile of cash.
- Medical Devices
- Generic Drugs
- Specialty Pharmaceuticals
- Therapeutic Areas
- Immune Disorders
- Metabolic Disorders
- Neurology, Nervous System
- Renal System
- Respiratory, Pulmonary
- Mallinckrodt LLC
- Mallinckrodt Inc.
- Mallinckrodt Group, Inc.
- Mallinckrodt Pharmaceuticals
- Western Europe
- Parent & Subsidiaries
- Mallinckrodt PLC
- Senior Management
Mark Trudeau, Pres. & CEO
George Kegler, EVP and CFO, Interim
Steven Romano, MD, EVP, CSO
Matthew Harbaugh, President, Specialty Generics
Hugh O'Neill, EVP and Chief Commercial Officer
Dagmar Rosa-Bjorkeson, Chief Strategy and Corp Dev Officer
Frank Scholz, PhD, EVO and Chief Operations/Digital Innovation
- Contact Info
Phone: 17 8463 6700
3 Lotus Park
Staines-Upon-Thames, MO TW18 3AG
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.